Detection of lung cancer using weighted digital analysis of breath biomarkers

Clinica Chimica Acta

Volumn 393, Issue 2, 2008, Pages 76-84

  Phillips, Michael ^a,b   Altorki, Nasser ^c   Austin, John H M ^d   Cameron, Robert B ^e   Cataneo, Renee N ^a   Kloss, Robert ^f   Maxfield, Roger A ^d   Munawar, Muhammad I ^a   Pass, Harvey I ^g   Rashid, Asif ^a   Rom, William N ^g   Schmitt, Peter ^h   Wai, James ^a  

^a MENSSANA RESEARCH INC   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f DANBURY HOSPITAL   (United States)

^g NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^h Schmitt and Associates   (United States)

Author keywords

Biomarkers; Breath test; Diagnosis; Lung cancer; Multivariate analysis

Indexed keywords

BIOLOGICAL MARKER; VOLATILE AGENT; VOLATILE ORGANIC COMPOUND;

ALGORITHM; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; BREATH ANALYSIS; CANCER DIAGNOSIS; CANCER MODEL; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISCRIMINANT ANALYSIS; HUMAN; LUNG CANCER; LYMPH NODE; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE LINEAR REGRESSION ANALYSIS; MULTIVARIATE ANALYSIS; NONLINEAR SYSTEM; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROBABILITY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SMOKING; THORAX RADIOGRAPHY; WEIGHTED DIGITAL ANALYSIS;

BIOLOGICAL MARKERS; BREATH TESTS; HUMANS; LUNG NEOPLASMS; MULTIVARIATE ANALYSIS;

NICOTIANA TABACUM;

EID: 44649185592     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.02.021     Document Type: Article

References (27)

1. Ralph A., Jacups S., McGough K., McDonald M., and Currie B.J. The challenge of acute rheumatic fever diagnosis in a high-incidence population: a prospective study and proposed guidelines for diagnosis in Australia's Northern Territory. Heart Lung Circ 15 (2006) 113-118
2. Schneider J.P.G., Bitterlich N., Neu K., Velcovsky H.G., Morr H., and Katz N.E.E. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients. Anticancer Res 23 (2003) 899-906
3. Phillips M., Gleeson K., Hughes J.M., et al. Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet 353 (1999) 1930-1933
4. Phillips M., Cataneo R.N., Cummin A.R., et al. Detection of lung cancer with volatile markers in the breath. Chest 123 (2003) 2115-2123
5. Phillips M., Cataneo R., Ditkoff B., et al. Prediction of breast cancer using volatile biomarkers in the breath. Breast Cancer Res Treat (2006) (e-print prior to publication)
6. Phillips M., Cataneo R., Condos R., et al. Volatile biomarkers of pulmonary tuberculosis in the breath. Tubercul (Edinb) 87 (2007) 44-52
7. Phillips M., Boehmer J., Cataneo R., et al. Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study). J Heart Lung Transplant 23 (2004) 701-708
8. Phillips M., Altorki N., Austin J.H., et al. Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomarkers 3 (2007) 95-109
9. Phillips M., Herrera J., Krishnan S., Zain M., Greenberg J., and Cataneo R.N. Variation in volatile organic compounds in the breath of normal humans. J Chromatogr B Biomed Sci Appl 729 (1999) 75-88
10. Michiels S., Koscielny S., and Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365 (2005) 488-492
11. Sone S., Li F., Yang Z., et al. Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer 84 (2001) 25-32
12. Hoos A., Hepp H., Kaul S., Ahlert T., Bastert G., and Wallwiener D. Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer. Int J Cancer (Pred Oncol) 79 (1998) 8-12
13. Sharkey J.C.S., Behar R.J., Perez R., et al. Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy. J Endourol 14 (2000) 343-350
14. Ornstein D., Rayford W., Fusaro V., et al. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol 172 (2004) 1302-1305
15. Bergen Hr., Vasmatzis G., Cliby W., Johnson K., Oberg A., and Muddiman D. Discovery of ovarian cancer biomarkers in serum using NanoLC electrospray ionization TOF and FT-ICR mass spectrometry. Dis Markers 19 (2003-2004) 239-249
16. Kalgutkar A.S., Hatch H.L., Kosea F., et al. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a ]p yridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes. Biopharm Drug Dispos 27 (2006) 371-386
17. Mortensen B., Zahlsen K., and Nilsen O.G. Metabolic interaction of n-hexane and methyl ethyl ketone in vitro in a head space rat liver S9 vial equilibration system. Pharmacol Toxicol 82 (1998) 67-73
18. Hamuro Y., Molnar K.S., Coales S.J., Ouyang B., Simorellis A.K., and Pochapsky T.C. Hydrogen-deuterium exchange mass spectrometry for investigation of backbone dynamics of oxidized and reduced cytochrome P450(cam). J Inorg Biochem 102 (2008) 364-370
19. Takemoto K., Yamazaki H., Nakajima M., and Yokoi T. Genotoxic activation of benzophenone and its two metabolites by human cytochrome P450 s in SOS/umu assay. Mutat Res 519 (2002) 199-204
20. Vennerstrom J.L., Ager Jr. A.L., Andersen S.L., et al. Assessment of the antimalarial potential of tetraoxane WR 148999. Am J Trop Med Hyg 62 (2000) 573-578
21. Puatanachokchai R., Morimura K., Wanibuchi H., et al. Alpha-benzene hexachloride exerts hormesis in preneoplastic lesion formation of rat hepatocarcinogenesis with the possible role for hepatic detoxifying enzymes. Cancer Lett 240 (2006) 102-113
22. Patrauchan M.A., Florizone C., Dosanjh M., Mohn W.W., Davies J., and Eltis L.D. Catabolism of benzoate and phthalate in Rhodococcus sp. strain RHA1: redundancies and convergence. J Bacteriol 187 (2005) 4050-4063
23. Bertea C.M., Schalk M., Karp F., Maffei M., and Croteau R. Demonstration that menthofuran synthase of mint (Mentha) is a cytochrome P450 monooxygenase: cloning, functional expression, and characterization of the responsible gene. Arch Biochem Biophys 390 (2001) 279-286
24. Urlacher V.B., Makhsumkhanov A., and Schmid R.D. Biotransformation of beta-ionone by engineered cytochrome P450 BM-3. Appl Microbiol Biotechnol 70 (2006) 53-59
25. A. Jemal, R.C. Tiwari, T. Murray, et al. Cancer Stat, 2004. CA Cancer J Clin 2004;54:8-29.
26. Henschke C.I., Yankelevitz D.F., Libby D.M., Pasmantier M.W., Smith J.P., and Miettinen O.S. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355 (2006) 1763-1771
27. Mascalchi M., Belli G., Zappa M., et al. Risk-benefit analysis of X-ray exposure associated with lung cancer screening in the Italung-CT trial. AJR 187 (2006) 421-429